The FDA granted orphan designation to a treatment of myotonic dystrophy type 1 being developed by Vertex Pharmaceuticals, according to a post to the agency’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Shopify, Spotify added to ‘Signature Picks’ portfolio at Wells Fargo
- Eli Lilly named new top large pharma pick at Wells Fargo
- RMR Group announces early renewal of Vertex Pharmaceuticals lease
- Vertex Pharmaceuticals annoucnes Casgevy reimbursement agreement in England
- Buffett trims Apple stake, delay worries dent Nvidia: Monday Buzz
Questions or Comments about the article? Write to editor@tipranks.com